Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial

Abstract Brief summary In early symptomatic COVID-19 treatment, high dose oral favipiravir did not accelerate viral clearance. Background Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been rec...

Full description

Bibliographic Details
Main Authors: Viravarn Luvira, William H. K. Schilling, Podjanee Jittamala, James A. Watson, Simon Boyd, Tanaya Siripoon, Thundon Ngamprasertchai, Pedro J. Almeida, Maneerat Ekkapongpisit, Cintia Cruz, James J. Callery, Shivani Singh, Runch Tuntipaiboontana, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Srisuda Keayarsa, Wanassanan Madmanee, Renato S. Aguiar, Franciele M. Santos, Pongtorn Hanboonkunupakarn, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Mallika Imwong, Walter R. J. Taylor, Vasin Chotivanich, Kesinee Chotivanich, Sasithon Pukrittayakamee, Arjen M. Dondorp, Nicholas P. J. Day, Mauro M. Teixeira, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Nicholas J. White, the PLATCOV Collaborative Group
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Infectious Diseases
Subjects:
Favipiravir
SARS-CoV-2
COVID-19
Early treatment
Antiviral efficacy
Pharmacometrics
Online Access:https://doi.org/10.1186/s12879-023-08835-3

Similar Items

Similar Items